Formulations maker V-Ensure lands $17.5m investment from Bahrain's Investcorp

India Pharma Outlook Team | Monday, 21 February 2022

 India Pharma Outlook Team

In a $17.5 million agreement, Bahrain fund manager investcorp acquires a stake in India's specialist formulations maker V-Ensure Pharma Technologies. Investcorp and Tanas Capital, a private investment business, led the round of fundraising.

This is the Gulf firm's third healthcare venture in India, and its first in the pharmaceutical industry. Founded in 2010, V-Ensure is a prominent creator of specialist formulations for complicated generics. It does so in the interest of "controlled marketplaces that do not infringe on any current patents." The business also specializes in designing end-to-end strategies for obtaining regulatory clearances for commercialization of these

compounds by handling all of the relevant processes and documents required by the regulator. According to Gulf News, this investment will fund V-Ensure’s pursuit of growth opportunities across North America, Europe and other markets for its products. V-Ensure has developed solid oral, liquid oral and injectable products for more than 45 clients in Europe, North America, China, Australia and Brazil. Gaurav Sharma, Head of Private Equity, Investcorp India, said, “As our first pharmaceutical deal in India, we are confident that healthcare globally will continue to be center stage for the future. V-Ensure is a renowned name among India-based pharmaceutical research organizations.

Over the last 10 years, V-Ensure has maintained its position as a ‘Contract Research Organization’. A team of 150 scientists plus head pharmaceutical development programmes for major pharmaceutical markets. Satyanarayana Vemula, CEO of V-Ensure added “With the backing of Investcorp’s experienced team and global network, we believe that we will be well positioned to significantly accelerate our growth.”

© 2025 India Pharma Outlook. All Rights Reserved.